Thromboembolism – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Thromboembolism – Pipeline Review, H2 2017’, provides an overview of the Thromboembolism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thromboembolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Thromboembolism

The report reviews pipeline therapeutics for Thromboembolism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Thromboembolism therapeutics and enlists all their major and minor projects

The report assesses Thromboembolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Thromboembolism

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Thromboembolism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Thromboembolism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Company Ltd

F. Hoffmann-La Roche Ltd

Gamma Therapeutics Inc

GlycoMimetics Inc

Green Cross Corp

Ionis Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thromboembolism - Overview

Thromboembolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism - Companies Involved in Therapeutics Development

Bayer AG

China Biologic Products Inc

Daiichi Sankyo Company Ltd

F. Hoffmann-La Roche Ltd

Gamma Therapeutics Inc

GlycoMimetics Inc

Green Cross Corp

Ionis Pharmaceuticals Inc

Portola Pharmaceuticals Inc

Verseon Corp

Thromboembolism - Drug Profiles

antithrombin III (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betrixaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gammarin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GCC-2107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAP-ANV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thromboembolism - Dormant Projects

Thromboembolism - Discontinued Products

Thromboembolism - Product Development Milestones

Featured News & Press Releases

Jun 28, 2017: U.S. FDA Grants Priority Review of XARELTO (rivaroxaban) sNDA for a 10 mg Dose to Reduce the Risk of Recurrent Venous Thromboembolism

Jun 23, 2017: FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients

Apr 28, 2017: Rivaroxaban 10 mg Once Daily from Bayer Submitted to U.S. FDA as Additional Dose Option to Reduce the Risk of Recurrent Venous Thromboembolism

Mar 18, 2017: Bayer's Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study

Mar 13, 2017: Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism in Cancer Patients

Mar 07, 2017: Portola Pharmaceuticals Announces Betrixaban Presentations at ACC.17

Mar 06, 2017: EINSTEIN CHOICE Study with Bayer's Rivaroxaban Accepted for Late-Breaking Clinical Trial Presentation at ACC.17

Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting

Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban

Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Dec 06, 2016: New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment

Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants

Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

Nov 28, 2016: Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH 2016

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thromboembolism, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Thromboembolism – Pipeline by Bayer AG, H2 2017

Thromboembolism – Pipeline by China Biologic Products Inc, H2 2017

Thromboembolism – Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Thromboembolism – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Thromboembolism – Pipeline by Gamma Therapeutics Inc, H2 2017

Thromboembolism – Pipeline by GlycoMimetics Inc, H2 2017

Thromboembolism – Pipeline by Green Cross Corp, H2 2017

Thromboembolism – Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Thromboembolism – Pipeline by Portola Pharmaceuticals Inc, H2 2017

Thromboembolism – Pipeline by Verseon Corp, H2 2017

Thromboembolism – Dormant Projects, H2 2017

Thromboembolism – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Thromboembolism, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports